Literature DB >> 29884612

Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis.

Ming Yu1, Sean K Maden1, Matthew Stachler2,3, Andrew M Kaz1,4,5, Jessica Ayers1, Yuna Guo1, Kelly T Carter1, Amber Willbanks1, Tai J Heinzerling1, Rachele M O'Leary1, Xinsen Xu3, Adam Bass3,6, Apoorva K Chandar7,8, Amitabh Chak7,9,10, Robin Elliott10,11, Joseph E Willis10,11, Sanford D Markowitz8,10, William M Grady1,4.   

Abstract

OBJECTIVE: To identify and characterise DNA methylation subtypes in oesophageal adenocarcinoma (EAC) and its precursor Barrett's oesophagus (BE).
DESIGN: We performed genome-wide DNA methylation profiling on samples of non-dysplastic BE from cancer-free patients (n=59), EAC (n=23), normal squamous oesophagus (n=33) and normal fundus (n=9), and identified methylation subtypes using a recursively partitioned mixture model. We assessed genomic alterations for 9 BE and 22 EAC samples with massively parallel sequencing of 243 EAC-associated genes, and we conducted integrative analyses with transcriptome data to identify epigenetically repressed genes. We also carried out in vitro experiments treating EAC cell lines with 5-Aza-2'-Deoxycytidine (5-Aza-dC), short hairpin RNA knockdown and anticancer therapies.
RESULTS: We identified and validated four methylation subtypes of EAC and BE. The high methylator subtype (HM) of EAC had the greatest number of activating events in ERBB2 (p<0.05, Student's t-test) and the highest global mutation load (p<0.05, Fisher's exact test). PTPN13 was silenced by aberrant methylation in the HM subtype preferentially and in 57% of EACs overall. In EAC cell lines, 5-Aza-dC treatment restored PTPN13 expression and significantly decreased its promoter methylation in HM cell lines (p<0.05, Welch's t-test). Inhibition of PTPN13 expression in the SK-GT-4 EAC cell line promoted proliferation, colony formation and migration, and increased phosphorylation in ERBB2/EGFR/Src kinase pathways. Finally, EAC cell lines showed subtype-specific responses to topotecan, SN-38 and palbociclib treatment.
CONCLUSIONS: We identified and characterised methylator subtypes in BE and EAC. We further demonstrated the biological and clinical relevance of EAC methylator subtypes, which may ultimately help guide clinical management of patients with EAC. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  dysplasia; gastrointestinal cancer; methylation

Mesh:

Substances:

Year:  2018        PMID: 29884612      PMCID: PMC6565505          DOI: 10.1136/gutjnl-2017-314544

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  51 in total

1.  PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase.

Authors:  Murielle Glondu-Lassis; Mathilde Dromard; Magali Lacroix-Triki; Philippe Nirdé; Carole Puech; Dora Knani; Dany Chalbos; Gilles Freiss
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

2.  Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma.

Authors:  Jihun Kim; Cameron Fox; Shouyong Peng; Mark Pusung; Eirini Pectasides; Eric Matthee; Yong Sang Hong; In-Gu Do; Jiryeon Jang; Aaron R Thorner; Paul Van Hummelen; Anil K Rustgi; Kwok-Kin Wong; Zhongren Zhou; Ping Tang; Kyoung-Mee Kim; Jeeyun Lee; Adam J Bass
Journal:  J Clin Invest       Date:  2014-11-17       Impact factor: 14.808

3.  Oncotator: cancer variant annotation tool.

Authors:  Alex H Ramos; Lee Lichtenstein; Manaswi Gupta; Michael S Lawrence; Trevor J Pugh; Gordon Saksena; Matthew Meyerson; Gad Getz
Journal:  Hum Mutat       Date:  2015-03-16       Impact factor: 4.878

4.  The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma.

Authors:  Carlo C Maley; Patricia C Galipeau; Xiaohong Li; Carissa A Sanchez; Thomas G Paulson; Patricia L Blount; Brian J Reid
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

5.  Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content.

Authors:  Salvatore Pece; Daniela Tosoni; Stefano Confalonieri; Giovanni Mazzarol; Manuela Vecchi; Simona Ronzoni; Loris Bernard; Giuseppe Viale; Pier Giuseppe Pelicci; Pier Paolo Di Fiore
Journal:  Cell       Date:  2010-01-08       Impact factor: 41.582

6.  A framework for variation discovery and genotyping using next-generation DNA sequencing data.

Authors:  Mark A DePristo; Eric Banks; Ryan Poplin; Kiran V Garimella; Jared R Maguire; Christopher Hartl; Anthony A Philippakis; Guillermo del Angel; Manuel A Rivas; Matt Hanna; Aaron McKenna; Tim J Fennell; Andrew M Kernytsky; Andrey Y Sivachenko; Kristian Cibulskis; Stacey B Gabriel; David Altshuler; Mark J Daly
Journal:  Nat Genet       Date:  2011-04-10       Impact factor: 38.330

7.  Hunk/Mak-v is a negative regulator of intestinal cell proliferation.

Authors:  Karen R Reed; Igor V Korobko; Natalia Ninkina; Elena V Korobko; Ben R Hopkins; James L Platt; Vladimir Buchman; Alan R Clarke
Journal:  BMC Cancer       Date:  2015-03-08       Impact factor: 4.430

8.  Paired exome analysis of Barrett's esophagus and adenocarcinoma.

Authors:  Matthew D Stachler; Amaro Taylor-Weiner; Shouyong Peng; Aaron McKenna; Agoston T Agoston; Robert D Odze; Jon M Davison; Katie S Nason; Massimo Loda; Ignaty Leshchiner; Chip Stewart; Petar Stojanov; Sara Seepo; Michael S Lawrence; Daysha Ferrer-Torres; Jules Lin; Andrew C Chang; Stacey B Gabriel; Eric S Lander; David G Beer; Gad Getz; Scott L Carter; Adam J Bass
Journal:  Nat Genet       Date:  2015-07-20       Impact factor: 38.330

9.  Comprehensive molecular portraits of human breast tumours.

Authors: 
Journal:  Nature       Date:  2012-09-23       Impact factor: 49.962

10.  TUSC1, a putative tumor suppressor gene, reduces tumor cell growth in vitro and tumor growth in vivo.

Authors:  Zhihong Shan; Abbas Shakoori; Sohrab Bodaghi; Paul Goldsmith; Jen Jin; Jonathan S Wiest
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

View more
  18 in total

Review 1.  Epigenetic Aging: More Than Just a Clock When It Comes to Cancer.

Authors:  Ming Yu; William M Grady; William D Hazelton; Georg E Luebeck
Journal:  Cancer Res       Date:  2019-11-06       Impact factor: 12.701

2.  Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data.

Authors:  SriGanesh Jammula; Annalise C Katz-Summercorn; Xiaodun Li; Constanza Linossi; Elizabeth Smyth; Sarah Killcoyne; Daniele Biasci; Vinod V Subash; Sujath Abbas; Adrienn Blasko; Ginny Devonshire; Amber Grantham; Filip Wronowski; Maria O'Donovan; Nicola Grehan; Matthew D Eldridge; Simon Tavaré; Rebecca C Fitzgerald
Journal:  Gastroenterology       Date:  2020-02-04       Impact factor: 22.682

3.  Expression of DNA Mismatch Repair Proteins, PD1 and PDL1 in Barrett's Neoplasia.

Authors:  James J Saller; Linda B Mora; Aejaz Nasir; Zachary Mayer; Mohammad Shahid; Domenico Coppola
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

4.  Novel DNA Methylation Biomarker Panel for Detection of Esophageal Adenocarcinoma and High-Grade Dysplasia.

Authors:  Ming Yu; Helen R Moinova; Sanford D Markowitz; William M Grady; Amber Willbanks; Victoria K Cannon; Ting Wang; Kelly Carter; Andrew Kaz; Deepti Reddi; John Inadomi; Georg Luebeck; Prasad G Iyer; Marcia I Canto; Jean S Wang; Nicholas J Shaheen; Prashanti N Thota; Joseph E Willis; Thomas LaFramboise; Amitabh Chak
Journal:  Clin Cancer Res       Date:  2022-09-01       Impact factor: 13.801

5.  Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junction.

Authors:  Kentaro Sugano; Stuart Jon Spechler; Emad M El-Omar; Kenneth E L McColl; Kaiyo Takubo; Takuji Gotoda; Mitsuhiro Fujishiro; Katsunori Iijima; Haruhiro Inoue; Takashi Kawai; Yoshikazu Kinoshita; Hiroto Miwa; Ken-Ichi Mukaisho; Kazunari Murakami; Yasuyuki Seto; Hisao Tajiri; Shobna Bhatia; Myung-Gyu Choi; Rebecca C Fitzgerald; Kwong Ming Fock; Khean-Lee Goh; Khek Yu Ho; Varocha Mahachai; Maria O'Donovan; Robert Odze; Richard Peek; Massimo Rugge; Prateek Sharma; Jose D Sollano; Michael Vieth; Justin Wu; Ming-Shiang Wu; Duowu Zou; Michio Kaminishi; Peter Malfertheiner
Journal:  Gut       Date:  2022-06-20       Impact factor: 31.793

Review 6.  Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer.

Authors:  William M Grady; Ming Yu; Sanford D Markowitz
Journal:  Gastroenterology       Date:  2020-12-03       Impact factor: 22.682

7.  Validation of a methylated DNA marker panel for the nonendoscopic detection of Barrett's esophagus in a multisite case-control study.

Authors:  Prasad G Iyer; William R Taylor; Seth W Slettedahl; Ramona L Lansing; Lois L Hemminger; Frances K Cayer; Douglas W Mahoney; Maria Giakoumopoulos; Hatim T Allawi; Tsung-Teh Wu; Kenneth K Wang; Herbert C Wolfsen; Eduardo Antpack; John B Kisiel
Journal:  Gastrointest Endosc       Date:  2021-04-20       Impact factor: 10.396

8.  Barrett's Esophagus and Esophageal Adenocarcinoma Biomarkers.

Authors:  William M Grady; Ming Yu; Sanford D Markowitz; Amitabh Chak
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-10-22       Impact factor: 4.254

9.  Computational modelling suggests that Barrett's oesophagus may be the precursor of all oesophageal adenocarcinomas.

Authors:  Kit Curtius; Joel H Rubenstein; Amitabh Chak; John M Inadomi
Journal:  Gut       Date:  2020-11-24       Impact factor: 31.793

10.  Specific DNA methylation markers in the diagnosis and prognosis of esophageal cancer.

Authors:  DaPeng Li; Lei Zhang; YuPeng Liu; HongRu Sun; Justina Ucheojor Onwuka; ZhiGang Zhao; WenJing Tian; Jing Xu; YaShuang Zhao; HongYu Xu
Journal:  Aging (Albany NY)       Date:  2019-12-13       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.